Mersana Therapeutics, Inc.
MRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $175 | $269 | $549 | $439 |
| - Cash | $108 | $175 | $129 | $178 |
| + Debt | $29 | $34 | $37 | $38 |
| Enterprise Value | $96 | $129 | $456 | $299 |
| Revenue | $40 | $37 | $27 | $0 |
| % Growth | 9.9% | 38.7% | 61,716.3% | – |
| Gross Profit | $40 | $37 | $27 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$63 | -$166 | -$200 | -$168 |
| % Margin | -156.2% | -450.6% | -752.3% | -390,553.5% |
| Net Income | -$69 | -$172 | -$204 | -$170 |
| % Margin | -170.9% | -465.8% | -768.3% | -395,488.4% |
| EPS Diluted | -14.12 | -36.96 | -54.51 | -60.24 |
| % Growth | 61.8% | 32.2% | 9.5% | – |
| Operating Cash Flow | -$82 | -$169 | -$49 | -$140 |
| Capital Expenditures | -$0 | -$2 | -$2 | -$1 |
| Free Cash Flow | -$82 | -$171 | -$52 | -$141 |